ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) just unveiled an update. ResMed Inc. has ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

Wilsons analyst Shane Storey downgraded Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report) to a ...